Langerhans Cell Histiocytosis
📧 Sign up to get email alerts when something new happens for Langerhans Cell Histiocytosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis [Phase 2]
This clinical trial update describes a Phase 2 study of tovorafenib (DAY101) as a potential treatment for progressive, relapsed, or refracto…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) [Phase 2]
Phase 2 update from the Pediatric MATCH trial describes targeted therapies matched to tumor genetics in pediatric patients with relapsed or …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) [Phase 2]
This update reports on a Phase 2 pediatric MATCH trial evaluating ensartinib for patients with relapsed or refractory ALK- or ROS1-genomic a…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis [Phase 2, Phase 3]
The LCH-IV international collaborative treatment protocol for children and adolescents with Langerhans cell histiocytosis is described, span…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib [Phase 2]
A Phase 2 clinical trial is evaluating trametinib, a MEK inhibitor, as a targeted treatment for Langerhans Cell Histiocytosis and is current…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis [Phase 2]
An ongoing Phase 2 trial is evaluating and optimizing the timing and dosing of vemurafenib in juvenile patients with BRAF V600E–positive ref…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]
Phase 2 pediatric MATCH trial evaluating IDH1-mutant tumors for response to ivosidenib; results for recurrent and refractory solid tumors, l…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Project: Every Child for Younger Patients With Cancer
Clinical trial update from the Children's Oncology Group shows that the multi-indication pediatric trial 'Project: Every Child for Younger P…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. [Phase 2, Phase 3]
The DETERMINE trial's Arm 07 is studying dabrafenib plus trametinib in patients with BRAF V600 mutation-positive cancers across age groups; …
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis [NA]
A clinical trial update indicates status is recruiting for a study of Modified LCH-III regimen with or without Luvometinib in pediatric mult…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease [NA]
A clinical trial update indicates a study examining the molecular basis of Castleman disease, Langerhans cell histiocytosis, and non-Langerh…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions [NA]
A pediatric clinical trial is evaluating Luvometinib for Langerhans Cell Histiocytosis with special-site single/multifocal bone lesions; the…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Inherited Genetic Susceptibility in Langerhans Cell Histiocytosis (LCH)
Clinical trial update indicating inherited genetic susceptibility in Langerhans cell histiocytosis (LCH); the study is currently active but …
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial [Phase 2]
This update reports on a Phase 2 pediatric MATCH trial evaluating selpercatinib for patients with activating RET gene alterations across adv…
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Q702 for the Treatment of Patients With Hematologic Malignancies [Phase 1]
This entry notes a Phase 1 clinical trial (Q702) for hematologic malignancies led by Mayo Clinic, currently recruiting and including histioc…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of the XTD regimen (Selinexor, Thalidomide, and Dexamethasone) in adults with rela…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH [Phase 2]
A Phase 2 clinical trial is evaluating the efficacy and safety of combining low-dose cytarabine with thalidomide in adults with untreated La…
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders [Phase 2]
Phase 2 clinical trial update evaluating cobimetinib in refractory Langerhans cell histiocytosis and other histiocytic disorders, currently …
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: Mirdametinib in Histiocytic Disorders [Phase 2]
Phase 2 clinical trial evaluating mirdametinib for histiocytic disorders including Langerhans cell histiocytosis, Juvenile xanthogranuloma, …
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) [Phase 3]
A Phase 3 clinical trial comparing vinblastine plus prednisone versus cytarabine alone for Langerhans cell histiocytosis is currently recrui…
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation [Phase 1, Phase 2]
This document provides an update on a phase 1/2 clinical trial evaluating CD34+ stem cell selection for patients receiving allogeneic stem c…
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children [Phase 2]
A Phase 2 clinical trial is evaluating the combination of Darafenib or Trametinib with Clofarabine for high-risk, recurrent, or refractory L…
-
CLINICAL_TRIALS trial_result · 2025-06-11Clinical Trial Update: Histiocytic Disorder Follow-up Study
A University of Alabama at Birmingham-sponsored clinical trial update indicates recruiting for a histiocytic disorder follow-up study, inclu…
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial [Phase 2]
Phase 2 pediatric MATCH trial results for Tipifarnib in HRAS-altered solid tumors and histiocytic disorders; the study has posted results an…
-
CLINICAL_TRIALS trial_result · 2025-04-25Clinical Trial Update: Lenalidomide for Adult Histiocyte Disorders [Phase 2]
Phase 2 trial results of lenalidomide in adults with Langerhans cell histiocytosis, Erdheim-Chester disease, and histiocytic sarcoma; the st…